BioNTech: The Market Is Pricing Low Oncology Success

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

BioNTech SE (BNTX) Rallying on Solid Oncology Strategy

BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from ...

Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum Shift

BioNTech share performance snapshot BioNTech (NasdaqGS:BNTX) has seen mixed share price moves recently, with a small 1 day decline, a gain over the past week, a loss over the past month, and a ...
Nasdaq

BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...